Clinical Trial Update: Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluated the safety of anti-IL-6 receptor antibodies to reduce allo-sensitization after kidney allograft nephrectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Failure
• Kidney Transplantation

Drugs mentioned

• Anti-IL-6 receptor antibodies

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Kidney Transplantation, Graft Failure | Phase 2 | Status: COMPLETED